个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Sun, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] * ; Hu, Chaosu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lin, Qin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Gao, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhu, Xiaodong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Hao, Junfang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lang, Jin Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Peiguo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Ye, Ming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Li, Xia[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Xu, Benhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wu, Rong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Bai, Chunmei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; You, Qingshan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Chen, Xiaozhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Jun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Hu, Desheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wu, Gang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Pan, Jian-Ji[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ;
机构： [1]Beijing Canc Hosp, Beijing, Peoples R China [2]Fudan Univ Canc Ctr, Shanghai, Peoples R China [3]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China [4]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China [5]Zhengzhou Univ, Henan Tumor Hosp, Tumor Hosp, Zhengzhou, Peoples R China [6]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China [7]Shandong Canc Hosp, Jinan, Peoples R China [8]Univ Elect Sci & Technol China, Radiat Oncol Key Lab Sichuan Prov, Dept Radiat Oncol, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China [9]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [10]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China [11]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [12]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China [13]China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China [14]Peking Union Med Coll Hosp, Chinese Acad Med Sci, Beijing, Peoples R China [15]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [16]Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China [17]Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang, Peoples R China [18]Hubei Canc Hosp, Wuhan, Peoples R China [19]Huazhong Univ Sci & Technol, Wuhan, Peoples R China [20]Fujian Canc Hosp, Fuzhou, Peoples R China
出处：
ISSN：
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Beijing Canc Hosp, Beijing, Peoples R China [2]Fudan Univ Canc Ctr, Shanghai, Peoples R China [3]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China [4]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China [5]Zhengzhou Univ, Henan Tumor Hosp, Tumor Hosp, Zhengzhou, Peoples R China [6]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China [7]Shandong Canc Hosp, Jinan, Peoples R China [8]Univ Elect Sci & Technol China, Radiat Oncol Key Lab Sichuan Prov, Dept Radiat Oncol, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China [9]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [10]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China [11]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [12]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China [13]China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China [14]Peking Union Med Coll Hosp, Chinese Acad Med Sci, Beijing, Peoples R China [15]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [16]Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China [17]Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang, Peoples R China [18]Hubei Canc Hosp, Wuhan, Peoples R China [19]Huazhong Univ Sci & Technol, Wuhan, Peoples R China [20]Fujian Canc Hosp, Fuzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Sun Yan,Hu Chaosu,Lin Qin,et al.Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Sun, Yan,Hu, Chaosu,Lin, Qin,Gao, Li,Wang, Jianhua...&Pan, Jian-Ji.(2022).Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Sun, Yan,et al."Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号